Inozyme Pharma

Today we announced that Petra Duda, M.D., Ph.D. has been appointed our Chief Medical Officer. Dr. Duda will help guide the development of our lead program, INZ-701, which is being studied in a pivotal clinical trial in children with ENPP1 Deficiency. She brings more than two decades of global clinical development, medical affairs, and regulatory leadership to Inozyme Pharma, and has deep expertise in rare and ultra-rare diseases.

You can read more about Dr. Duda in our press release: https://bit.ly/4kgr4Ya

Today we celebrate , honoring groundbreaking achievements in genetics, particularly the discovery of the DNA double helix by James Watson and Francis Crick in 1953, and the completion of the Human Genome Project in 2003.

At Inozyme Pharma, we’re building upon these critical achievements as we work to better understand and develop treatments for people living with rare diseases that affect bone health and blood vessel function. As part of this commitment, we support no-cost genetic testing and genomic newborn screening programs in a number of countries to facilitate earlier and accurate diagnosis. We’ve also broadened our physician outreach efforts through medical education at key conferences and scientific engagement.